Description

Letrotex 2.5 contains pharmaceutical-grade Letrozole, a potent non-steroidal aromatase inhibitor commonly used in laboratory research to study estrogen biosynthesis inhibition and related hormonal pathways. Manufactured by Novotex Pharma, this oral formulation is presented as blister-packed tablets, providing reliable dosing for laboratory and analytical use in endocrine and pharmacological studies.

▪ Product Details

• Active Ingredient: Letrozole

• Dosage Strength: 2.5 mg per tablet

• Form: Oral tablets

• Brand: Novotex Pharma

• Package Size: 60 tablets (boxed, blister-packed)

• Intended Use: Laboratory and analytical use

▪ Pharmacokinetics

Letrozole is rapidly absorbed after oral administration with peak plasma concentrations achieved within 1–2 hours. It has a half-life of approximately 2 days and is extensively metabolized in the liver by cytochrome P450 enzymes. The compound effectively inhibits aromatase enzyme activity, reducing estrogen synthesis, which is valuable for in-vitro and in-vivo modeling of estrogen-dependent processes.

▪ Usage Recommendations

Standard lab protocols simulate oral administration of 2.5 mg daily, adjusted per experimental design. Tablets should be stored in original blister packaging to maintain compound stability and should be handled according to standard laboratory safety practices.

▪ Disclaimer

This product is intended strictly for laboratory research and analytical use. Not for human consumption or medical treatment. Not suitable for individuals under 18, pregnant or breastfeeding women, or those with health conditions. Must be handled per local regulations and laboratory safety standards.